ABBV vs ALKS

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

ALKS exhibits a weak Piotroski F-Score of 4/9, indicating marginal financial health, and lacks an Altman Z-Score, raising concerns about default risk. Despite a strong Graham Number of $18.80 and intrinsic value estimate of $10.01, the current price of $27.76 trades at a significant premium, especially given deteriorating growth and profitability metrics. The company shows a sharp decline in revenue and earnings (YoY: -10.6% and -67.0%), with recent quarterly earnings missing expectations and negative Q/Q trends. Insider selling activity over the past six months further undermines confidence, despite strong historical earnings surprises. The market appears to be pricing in future recovery, but current fundamentals suggest caution.